The Effect of a Probiotic Strain on Aspirin-induced GI Damage
Stopped early · Not applicable · Has a placebo group
Conditions studied: Reduction of Small Intestinal Ulceration Risk
In brief
The primary objective of this trial is to investigate if a daily dose of minimum 50 billion CFU of Bif195 reduces the risk of small-intestinal tissue damage in an acetylsalicylic acid challenge model as assessed by video capsule endoscopy in a healthy US population aged 40 - 60 years.
Key facts
- Study ID
- NCT03910322
- Run by
- Chr Hansen
- People needed
- 30
- Starts
- 2019-08-19
- Expected to finish
- 2019-12-01
- Last updated by the study team
- 2020-06-26
Who can join
Age: 40 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Written informed consent
- Healthy and without any gastrointestinal discomfort/pain symptoms
- Age 40-60 years of both genders (aim of minimum 1/3 of each gender in each arm)
- Willing and able to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial
You may not qualify if…
- Abdominal surgery which, as judged by the investigator, might affect the GI function (except appendectomy and cholecystectomy)
- History of peptic ulcer disease
- Any known bleeding disorder
- Allergy to ASA
- Resting diastolic blood pressure ≥ 95 mmHg
- Resting systolic blood pressure ≥ 150 mmHg
- A current diagnosis of psychiatric disease
- Systemic use of antibiotics, steroids (except contraceptives) or antimicrobial medication in the last 2 months
- Daily usage of non-steroidal anti-inflammatory drugs in the last 2 months or incidental use in the last 2 weeks prior to screening (ASA, Ibuprofen, Diclofenac, Naproxen, Celecoxib, Mefenamic acid, Etoricoxib, Indometacin)
- Usage of medications, except contraceptives, in the last 2 weeks prior to screening
- Diagnosed inflammatory gastrointestinal disease and/or irritable bowel syndrome
- Any other disease that, by the Investigators discretion, could interfere with the intestinal barrier function of the subject
- Participation in other clinical trials in the past 2 months prior to screening
- Regular use of probiotics in the last month
- Smoking and/or frequent use of other nicotine products
- Desire and/or plans on changing current diet and/or exercise regime during the participation of this trial
- Use of laxatives, anti-diarrheals, anti-cholinergics and proton pump inhibitors within last 2 months prior to screening
- Use of immunosuppressant drugs within last 4 weeks prior to screening
- For Women: Pregnancy or lactation
Where it is running
- Atlantia Food Clinical Trials — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.